Sodium glucose transporter 2 inhibitors for heart failure

doi:10.4330/wjc.v18.i3.118227

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

Google Scholar

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=41

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=25

Publishing Process of This Article

Item

Count

Browse

Download

Sum=1

Mar 26, 2026 (publication date) through Mar 23, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Mar 26, 2026; 18(3): 118227
Published online Mar 26, 2026. doi: 10.4330/wjc.v18.i3.118227

Open in New Tab Full Size Figure Download Figure

Figure 1 Systemic effects of sodium glucose transporter 2 inhibitors. Physiological mechanisms and clinical outcomes from major cardiovascular outcome trials. Orange asterisks indicate effects with established statistical significance (P < 0.05) in major cardiovascular or renal outcome trials (e.g., EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure, DAPA-Chronic Kidney Disease). Unmarked items represent known physiological mechanisms. CD: Cardiovascular death; CKD: Chronic kidney disease; GFR: Glomerular filtration rate; HF: Heart failure; LV: Left ventricular.

Citation: Usuda D, Furukawa D, Imaizumi R, Ono R, Kaneoka Y, Nakajima E, Kato M, Sugawara Y, Shimizu R, Inami T, Sakurai R, Kawai K, Matsubara S, Tanaka R, Suzuki M, Shimozawa S, Hotchi Y, Osugi I, Katou R, Ito S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Nomura T, Sugita M. Sodium glucose transporter 2 inhibitors for heart failure. World J Cardiol 2026; 18(3): 118227
URL: https://www.wjgnet.com/1949-8462/full/v18/i3/118227.htm
DOI: https://dx.doi.org/10.4330/wjc.v18.i3.118227

Usuda D, Furukawa D, Imaizumi R, Ono R, Kaneoka Y, Nakajima E, Kato M, Sugawara Y, Shimizu R, Inami T, Sakurai R, Kawai K, Matsubara S, Tanaka R, Suzuki M, Shimozawa S, Hotchi Y, Osugi I, Katou R, Ito S, Mishima K, Kondo A, Mizuno K, Takami H, Komatsu T, Nomura T, Sugita M. Sodium glucose transporter 2 inhibitors for heart failure. World J Cardiol 2026; 18(3): 118227 [DOI: 10.4330/wjc.v18.i3.118227]

©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA